Alternativas farmacológicas a las transfusiones de sangre y componentes

https://doi.org/10.25100/cm.v25i.2.1795

Article Sidebar

HTML

Published: Nov 14, 1994
Issue: Vol. 25 No. 2 (1994)
Section Reviews

Publcation metrics

787 | 3472




 


Main Article Content

Authors

Armando Cortés B. Universidad del Valle
Abstract
Con la conciencia actual sobre los riesgos de las transfusiones, ha crecido el interés por sus alternativas farmacológicas. En esta revisión algunas se han evaluado en diversas situaciones clínicas y además, se resume su uso actual y varias de sus aplicaciones futuras. Se describe el uso de factores de crecimiento como la eritropoyetina, la reducción del sangrado perioperatorio con desmopresina, aprotinina, prosterenol y diprodamol, entre otros, así como la terapia con factores sintéticos de la coagulación en ciertas deficiencias congénitas y en sustitución de la sangre.
Author Biography

Armando Cortés B., Universidad del Valle

Profesor Titular, Departamento de Patología, Facultad de Salud, Universidad del Valle.Jefe de Laboratorio, Hospital Universitario del Valle. Director Banco de SangreCruz Roja Colombiana, Seccional Valle, Cali, Colombia
References

Goodnought LT, Shuck J. Blood transfusion in elective surgery: Review of risks, options and informed consent. Am J Surg 1990; 159: 602-09. DOI: https://doi.org/10.1016/S0002-9610(06)80079-6

Nance SJ (ed.) Blood safety: current challenges. Pp. 4-37. American Association of Blood Banks, Bethesda, 1992.

Forbes J, Anderson M, Anderson G, et al. Blood transfusion cost. A multicenter study. Transfusion 1991; 31: 318. DOI: https://doi.org/10.1046/j.1537-2995.1991.31491213295.x

Popovsky MA. Autologous blood transfusion in the 1990s. Where is it heading? Am J Clin Pathol 1992; 97: 297-300. DOI: https://doi.org/10.1093/ajcp/97.3.297

Nance SJ (ed.). Blood safety: current challenges. Pp. 151-67. Amercian Association of Blood Banks, Bethesda, 1992.

Goodnought LA, Geha AJ. A new era in blood conservation. Ann Thorac Surg 1991; 51: 703-04. DOI: https://doi.org/10.1016/0003-4975(91)90108-3

Greene W, Winer S, Ransil B, Popovsky MA. Changes in transfusion practice in the EPO era. Transfusion 1991; 31: 58S.

Clinical applications of hematopoietic growth factors. Semin Hematol 1989; 26 (suppl. 2): 1-23.

Goodnought LT, Rudnicks S, Proce TH, et al. Increased autologous blood donation with recombinant human erythropoietin. N Engl J Med 1989; 321: 1163-68. DOI: https://doi.org/10.1056/NEJM198910263211705

Levine EA, Rosen AL, Goul SA, et al. Recombinant human erythropoietin and autologous blood donation. Surgery 1988; 104: 365-69.

Egrie JC, Eschbach JW, McGuire T, Adamson JW. Pharmacokinetics of recombinant human erythropoietin (rHuEPO) administered to hemodialysis (HD) patients. Kidney Int 1988; 33: 262.

Stockman JA. Erythropoientin off again on again. J Pediatric 1988; 442: 906-08. DOI: https://doi.org/10.1016/S0022-3476(88)80212-9

Goodnought LT, Brittenham G. Limitations of the erythropoietic response to serial phlebotomy. Implications for autologous blood donor programs. J Lab Clin Med 1990; 115: 28-35. DOI: https://doi.org/10.1097/00132586-199010000-00063

Goodnought LT, Wasman J, Corlucci K, et al. Limitactions in adequate storage of autologous blood. Arch Surg 1989; 124: 494-96. DOI: https://doi.org/10.1001/archsurg.1989.01410040104024

Kickler TS, Spivak JL. Effect of repeatedwhole blood donations on serum immunoreactive arythropoietin levels in autologous donors. JAMA 1988; 260: 65-7. DOI: https://doi.org/10.1001/jama.260.1.65

Gaudiani VA, Mason HDW. Preoperative erytropoietin in Jehovah's witnesses who requiere cardiac procedures. Ann Thorac Surg 1991; 51: 823-24. DOI: https://doi.org/10.1016/0003-4975(91)90139-H

Goodnought LT. Erythropoietin as a pharmacologic alternative to homologous blood transfusion in the surgical patient. Transfus Med Rev 1990; 4: 288-96. DOI: https://doi.org/10.1016/S0887-7963(90)70271-4

Goodnough LT. Blood and blood products. Pp. 157-65. In Orthopedic knowledge update III. Poss R (ed.). American Academy of Orthopedic Surgery, 1990.

Owings DV, Kruskall NS, Thurer RL, Donovan LM. Autologous blood donations prior to elective cardiac surgery. JAMA 1989; 262: 1963-68. DOI: https://doi.org/10.1001/jama.262.14.1963

Eschbach JB, Kelly MR, Haley NR, et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158-63. DOI: https://doi.org/10.1056/NEJM198907203210305

Raine AEG. Hypertension blood viscosity and cardiovascular morbidity in renal failure: implications for erythropoietin therapy. Lancet 1988; 1: 97-9. DOI: https://doi.org/10.1016/S0140-6736(88)90293-0

Bommer J, Ritz E, Weinrichs T, et al. Subcutaneos erythropoietin. Lancet 1988; 2: 406. DOI: https://doi.org/10.1016/S0140-6736(88)92886-3

Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythopoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990; 322: 1488-93. DOI: https://doi.org/10.1056/NEJM199005243222103

MacKinney RE, Maha MA, Connor EM, et al. A multicentar trial of oral zidovudine in children with advanced human inmunodeficiency virus disease. N Engl J Med 1991; 324: 1018-25. DOI: https://doi.org/10.1056/NEJM199104113241503

Spivak SL, Barnes DC, Fuchs E, Quinin TC. Serum immunoreactive erythropoietin in VIH-infected patients. JAMA 1989; 261: 3104. DOI: https://doi.org/10.1001/jama.1989.03420210052015

Walker RE, Parker RI, Kovacs JA, et al. Anemia and erythropoietin in patients with the acquired immunodficiency syndrome (AIDS) and Kaposi's sarcoma trated with zidovudine. Ann Intern Med 1988; 108: 372-76. DOI: https://doi.org/10.7326/0003-4819-108-3-372

Pincus T, Olsen NJ, Russell J, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumaroid arthritis. Am J Med 1990; 89: 161-68. DOI: https://doi.org/10.1016/0002-9343(90)90294-N

Miler CB, Jones RJ, Piant-Ados S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689. DOI: https://doi.org/10.1056/NEJM199006143222401

Rhodeau SM, Christense RD, Foss MP, et al. Responsiveness to recombinant human arythropoietin of marrow erythoid progenitors form infants with the "anemia of prematurity". J Pediatr 1988; 112: 935-40. DOI: https://doi.org/10.1016/S0022-3476(88)80223-3

Goldberg MA, Brugnara C, Dover GJ, et al. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 1990; 323: 366-67. DOI: https://doi.org/10.1056/NEJM199008093230602

Klingermann HG, Shepherd JD, Eaves CJ, Eaves AC. The role of erythropoietin and other growth factors in transfusion medicine. Transfus Med Rev 1991; 5: 33-47. DOI: https://doi.org/10.1016/S0887-7963(91)70191-0

Appelbaum FR. The clinical use of hematopoietic growth factors. Semin Hematol 1989; (suppl 3): 7-14.

Brito-Babapulle F. Therapeutic applications of the myeloid hematopoietic growth factors. Transfus Sci 1991; 12: 25. DOI: https://doi.org/10.1016/0955-3886(91)90006-O

Nemunaitis J. Granulocyte-macrophage colony-stimulanting factor: A review from preclinical development to clinical application. Transfusion 1993; 33: 70-83. DOI: https://doi.org/10.1046/j.1537-2995.1993.33193142315.x

Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulanting factor of fever and neutropenia induced by cemotheraphy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-70. DOI: https://doi.org/10.1056/NEJM199107183250305

Gabrilove JL, Jacubowski A, Scher H, et al. Effects of granulocyte colony-stimulanting factor of fever and neutropenia and associated morbidity due to chemotheraphy for transitional cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414-22. DOI: https://doi.org/10.1056/NEJM198806023182202

Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony stimulating factor on hematopoietic reconstitution after high dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 869. DOI: https://doi.org/10.1056/NEJM198804073181401

Lieschke GJ, Burgess AW. Drug therapy: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992; 327: 28-35; 99-106. DOI: https://doi.org/10.1056/NEJM199207093270207

Schulman S. DDAVP the multipotent drug in patient with coagulopahies. Transfus Med Rev 1991; 5: 132-44. DOI: https://doi.org/10.1016/S0887-7963(91)70200-9

Naorose-Abidi SM, Bond LR, Chitolie A, Bevan DH. Desmopressin therapy in patients with acquired Factor VIII inhibitors. Lancet 1988; 1: 366-67. DOI: https://doi.org/10.1016/S0140-6736(88)91169-5

Salzman EW, Weinstein MJ, Weinstraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. N Engl J Med 1986; 314: 1402-06. DOI: https://doi.org/10.1056/NEJM198605293142202

Hackman T, Gacone RD, Naiman SC, et al. A trial of desmopressin to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 1989; 321: 1437. DOI: https://doi.org/10.1056/NEJM198911233212104

Kentro TB, Lottenberg R, Kitcjhens CS. Clinical efficacy of desmopressin acetate for hemostatic control in patients with primary platet disorders undergoing surgery. Am J Hematol 1987; 24: 215-19. DOI: https://doi.org/10.1002/ajh.2830240213

Mannuci PM, Remuzi G, Pusineri F, et al. Deamino-8-D-arginine vasopresin shorters the bleeding time in uremia. N Engl J Med 1983; 308: 8-12. DOI: https://doi.org/10.1056/NEJM198301063080102

Havel M, Teufelsbauer H, Knobl P, et al. Effect of intraoperatorio aprotinin administration in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 1991; 101: 968-72. DOI: https://doi.org/10.1016/S0022-5223(19)36612-7

Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with dose apritinin (Trasylol). J Thorac Cardiocasc Surg 1989; 97: 362-72. DOI: https://doi.org/10.1016/S0022-5223(19)34573-8

Stump DC, Taylor FB, Nesheim ME, et al. Pathological fibrinolysis as a cause of clincal bleeding. Semin Thromb Hemost 1990; 16: 260-73. DOI: https://doi.org/10.1055/s-2007-1002678

Miller RA, May MW, Hendry WF, et al. The prevention of secundary hemorrhage after prostatectomy: the value of antifibrinolytic therapy. Br J Urol 1980; 52: 26-8. DOI: https://doi.org/10.1111/j.1464-410X.1980.tb02914.x

Goodnought LT, Johnston MFM, Shah T, Chernosky A. A two institution study of transfusion practice in open heart surgery. Am J Clin Pathol 1989; 91: 486-72. DOI: https://doi.org/10.1093/ajcp/91.4.468

Wenger RK, Lukasiewickz H, Mikuta BS, et al. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989; 97: 235. DOI: https://doi.org/10.1016/S0022-5223(19)35329-2

Kang Y, Lewis JH, Navalgund A, et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987; 66: 766-73. DOI: https://doi.org/10.1097/00000542-198706000-00010

Lambert CJ, Merngo-Rowe AJ, Levenson JE, et al. The treatment of postperfusion bleeding using E-aminocaproic acid, cryoprecipitate, fresh frozen plasma and protamine sulfate. Ann Thorac Surg 1979; 28: 440-44. DOI: https://doi.org/10.1016/S0003-4975(10)63153-0

Gardner FH, Helmer RE. Aminocapric acid: use in control of hemorrhage in patients with a megakaryocytic thrombocytopenia. JAMA 1980; 243: 35-7. DOI: https://doi.org/10.1001/jama.243.1.35

Bartholomev JR, Salgia R, Bell WR. Control of bleeding in patients with inmune and noimmune thrombocytopenia with aminocaproic acid. Arch Inter Med 1989; 149: 1959-61. DOI: https://doi.org/10.1001/archinte.1989.00390090039008

Glick R, Green D, Chung-Hsin T, et al. High dose epsilon aminocaproic acid prolongs the bleeding and intraoperative hemorrhage in paents with sub-arachnoid hemorrhage. Neurosurgery 1981; 9: 398-401. DOI: https://doi.org/10.1097/00006123-198110000-00009

Fobes CD, Barr RD, Reid G, et al. Tranexamic acid in control of hemorrhage after dental extraction of hemophilia and Christmas'disease. Br Med J 1972; 2: 311-13. DOI: https://doi.org/10.1136/bmj.2.5809.311

von Holstein CCSS, Eriksson SBS, Kallen R. tranexamic acid as and aid to reducing blood transfusion requeriments gastric and duodenal bleeding. Br J Med 1987; 294: 7-10. DOI: https://doi.org/10.1136/bmj.294.6563.7

Barer D, Ogilivie A, Henry D, et al. Cimetidine and tranexamic acid in the treatement of acute upper gastrointetsinal bleeding. N Engl J Med 1983; 308: 1571-75. DOI: https://doi.org/10.1056/NEJM198306303082606

Theoh KH, Christakis GT, Wetsel RD, et al. Dypiradamole preserved platelets and reduced blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1988; 96: 332-34. DOI: https://doi.org/10.1016/S0022-5223(19)35281-X

Silberstein LE, Williams LJ, Hughlett MA, et al. An autologous fibrinogenbased adhesive for use in otologic surgery. Transfusion 1988; 28: 319-21. DOI: https://doi.org/10.1046/j.1537-2995.1988.28488265257.x

Gibbe JW, Ness P. Fibrin glue: the perfect operative sealant? Transfusion 1990; 30: 741-47. DOI: https://doi.org/10.1046/j.1537-2995.1990.30891020337.x

Rumi MG, Colombo M, Gringeri A, Manucci, PM. High prevalence of antibody to hepatitis C virus in normal transaminases. Ann Inter Med 1990; 112: 379-80. DOI: https://doi.org/10.7326/0003-4819-112-5-379

Growe GH, Poon MC, Scarth I. International symposium on recombinant Factor VIII. Report of the proceedings. Transfus Med Rev 192; 6: 134-45. DOI: https://doi.org/10.1016/S0887-7963(92)70163-1

Schwartz RS, Abilgaard CF, Aleadort LM, et al. Human recombinant DNA-derived antihemophiliac factor (Factor VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323: 1800-05. DOI: https://doi.org/10.1056/NEJM199012273232604

Mannucci PM, Schimpf K, Brettler B, et al. Low risks for hepatitis C in hemophiliacs given a high-purity pasteurized factor VIII concentration. Ann Intern Med 1990; 113: 27-32. DOI: https://doi.org/10.7326/0003-4819-113-1-27

Luscher JM. Lack of inhibitor to monoclonal-antibody purified factor VIII concentred. Lancet 1990; 336: 1249-50. DOI: https://doi.org/10.1016/0140-6736(90)92863-D

Pierce GF, Lusher JM, Brownstein AP, et al. The use of purified clotting factor concentrates in hemophilia. JAMA 1989; 261: 3434-38. DOI: https://doi.org/10.1001/jama.261.23.3434

Kessler CM, Sachse K. Factor VIII: C inhibitor associated monoclonal antibody purified Factor VIII concentrate. Lancet 1990; 335: 4403. DOI: https://doi.org/10.1016/0140-6736(90)91282-F

Aronson D. The development of the technology and the capacity for the production of Factor VIII for the treatment of hemophilia A. Transfusion 1990; 30: 748-58. DOI: https://doi.org/10.1046/j.1537-2995.1990.30891020338.x

Cash JD. Coagulation Factor VIII concentrates and the market place. Lancet 1988; 1: 1270. DOI: https://doi.org/10.1016/S0140-6736(88)92083-1

Chang TMS. The use of modified hemoglobin as an oxygen carrying blood substitute. Transfus Med Rev 1989; 3: 213-18. DOI: https://doi.org/10.1016/S0887-7963(89)70081-X

Gould SA, Rosen AL, Sehgal LR. Fluosol-DA as a red cell substitute in acute anemia. N Engl J Med 1986; 314: 1653-56. DOI: https://doi.org/10.1056/NEJM198606263142601

Burhop KE, Farrell L, Dunlapn E, et al. Safety and efficacy evaluation of diaspirin cross-linked hemoglobin (DCLHb) in sheep and pigs (abstract). Transfusion 1991; 31: 54S.

How to Cite
Cortés B., A. (1994). Alternativas farmacológicas a las transfusiones de sangre y componentes. Colombia Medica, 25(2), 73–82. https://doi.org/10.25100/cm.v25i.2.1795
Usage statistics

Downloads

Download data is not yet available.

The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use